Trial · NCT04982354
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
NCT04982354, Phase 1, Phase 2, Withdrawn, Guenther Koehne
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia. Trials, record NCT04982354. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04982354
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
- NCT number
- NCT04982354
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Guenther Koehne
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CPX-351, Midostaurin, Busulfan, Melphalan, Fludarabine, CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor
- First posted
- 2021-07-29
- Last updated
- 2024-10-01
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in the complete remission rate | 3, 6, 12 and 24 months | Assess the complete remission rate following induction therapy with CPX-351 plus midostaurin when administered to patients |
| Primary | Change in Progression Free Survival (PFS) | 3, 6, 12 and 24 months | to determine the PFS of these patients following allo SCT. To estimate PFS the Kaplan-Meier method will be used. |
| Primary | Change in Overall Survival (OS) | 3, 6, 12 and 24 months | to determine the OS of these patients following allo SCT. To estimate OS the Kaplan-Meier method will be used. |
| Secondary | Change in the rate of Minimal Residual Disease (MRD) negativity | 3, 6, 12 and 24 months | Ascertain the rate of MRD negativity by next generation sequencing at sequential time post following induction treatment at complete remission prior to allo Stem Cell Transplantation (SCT) |
| Secondary | Correlation of Minimal Residual Disease (MRD) | 3, 6, 12 and 24 months | Correlation of duration of MRD negative status with duration of complete remission of these patients will be assessed using Spearman's correlation with reported p value. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04982354
GET https://conductscience.org/api/trials/v1/NCT04982354/registered